Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Workiva Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B), while Workiva Inc trades at $73.32 (market cap $4.01B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 31.8× Workiva Inc's market cap, and Vertex Pharmaceuticals Incorporated is more actively traded (1,487,944 versus 1,301,708). Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Workiva Inc for 21 Days on average.
| VRTX | WK | |
|---|---|---|
Market Cap | $127.55B | $4.01B |
Volume | 1,487,944 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $557.96 | $93.31 |
52-Week Low | $407.37 | $44.31 |
Typical Hold Time | 120 Days | 21 Days |
Enterprise Value | $121.68B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Workiva (WK) trades at $73.25, up 2.4% with strong bullish technical signals from moving averages. The company shows improving fundamentals with revenue growth from $885M in 2025 to $966M in 2026 and a shift to profitability with net income of $47M. Recent earnings beats and analyst optimism (16 buy ratings) support the positive momentum, though high valuation ratios (P/E 87.73) suggest premium pricing.
Outlook remains positive with consensus price target of $86 offering 17% upside potential. Key risks include elevated valuation metrics and competitive pressures in the regulatory technology space. The company's AI innovations and inclusion in analyst 'top picks' lists provide growth catalysts, but investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
